Daiichi Establishes New Japanese Vaccine Research Unit

Through the establishment of its new vaccine research unit, Daiichi Sankyo aims to enhance and broaden exploratory research for vaccines to prevent infectious diseases.

Japanese pharmaceutical company Daiichi Sankyo announced yesterday the establishment of a new Japanese vaccine research unit to be located in its Kasai R&D Center (Edogawa-ku, Tokyo).

Daiichi Sankyo has been strengthening and expanding its vaccine business in line with the Hybrid Business Model featured in its 2nd Mid-term Business Management Plan (FY2010-2012). In April 2011, Daiichi Sankyo set up a research unit inside the National Institute of Biomedical Innovation and is already performing exploratory vaccine research and continuously reinforcing and expanding R&D for new adjuvants.

Through the establishment of its new vaccine research unit, Daiichi Sankyo aims to enhance and broaden exploratory research for vaccines to prevent infectious disease